Rise Nano Optics to Commence Trading on the Canadian Securities Exchange Under the Symbol "EYE", Today, March 12, 2026

About this update from National Vision Holdings, Inc.

Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange (the "CSE"). Trading is expected to commence on the CSE under the symbol "EYE" at the open of markets on March 12, 2026. Inas Said, CEO of Rise commented, "Listing publicly represents an important milestone for Rise Nano Optics and provides the Company with a strong platform to accelerate growth and expand market awareness. With a robust intellectual property portfolio, FDA-registered optical technology and exposure to a global eyewear market valued in the hundreds of billions of dollars, Rise is well-positioned to execute on its commercialization strategy across North America and globally. Access to the public markets will support the scaling of our SPECTRAGUARD™ technology, the expansion of partnerships with optical labs and industry leaders and the continued development of innovative solutions designed to address the growing demand for advanced eye protection worldwide." Transforming Preventative Vision Care Rise is redefining the optical lens market with proprietary nanotechnology lens treatments that extend protection beyond traditional UV-only standards and into the 400-600nm high-energy visible light spectrum. A growing body of peer-reviewed research continues to examine the biological impact of high-energy visible wavelengths between 400-600nm, driving increased attention to advanced optical strategies. Unlike conventional eyewear solutions that focus solely on non-visible UV light, Rise's technology filters up to 90% of the wavelengths between 400-600nm while enhancing contrast, preserving natural colour perception and reducing glare and stray light. Addressing a Growing Global Medical Market Rise is currently pursuing multiple product development pathways aimed at a significant and expanding medical and consumer market, driven by rising rates of diabetic retinopathy, macular degeneration, cataracts, photophobia and migraine-related light sensitivity, which collectively affect over one billion people worldwide. With 92% of adults in the United States using some form of eyewear and the global eyewear market projected t...

View stock analysis, news, and events for National Vision Holdings, Inc.